BSEM BioStem Technologies Inc

BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025

BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025

Conference call and webcast to be held at 4:30 PM ET

POMPANO BEACH, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived products for advanced wound care, announces it will release its second quarter 2025 financial results on Thursday, August 14, 2025, and host a conference call and webcast at 4:30 PM ET.

The webcast will feature a review of second quarter results and an update on the Company’s Form 10 filing and Nasdaq uplisting, led by CEO Jason Matuszewski and CFO Michael Fortunato. To register for the event, please click .

Conference Call & Webcast Information:

  • Conference ID: 9695874
  • North America Toll-Free: (800) 715-9871
  • International Toll: +1 (646) 307-1963
  • Webcast Link: 

Join BioStem’s Distribution List & Social Media:

To follow the latest developments at BioStem, sign up for the Company’s email distribution list , and follow us on and .

About BioStem Technologies, Inc. (OTC: BSEM):

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for advanced wound care. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure.

BioStem’s quality management systems and standard operating procedures are accredited by the American Association of Tissue Banks (“AATB”) and adhere to Good Tissue Practices (cGTP) and Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, American Amnion™ and American Amnion™ AC. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit .

Forward-Looking Statements: 

Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate”, “plan,” “outlook,” “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects, and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production of its products in sufficient quantities to meet demand. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Contact BioStem Technologies, Inc.:

BioStem Technologies, Inc.

Adam Holdsworth

Director of Investor Relations

E-Mail: Phone: 917-497-9287

Or

Gilmartin Group

Philip Trip Taylor, Principal

E-Mail: 

Phone: 415-937-5406



EN
30/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioStem Technologies Inc

 PRESS RELEASE

BioStem Technologies Announces Insider Share Purchase by Chairman and ...

BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer POMPANO BEACH, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, discloses an insider purchase of common stock from Jason Matuszewski, Chairman and Chief Executive Officer of BioStem Technologies. Mr. Matuszewski purchased a total of 15,500 shares on August 19, 2025, totaling approximately $100,000. The purchases were made through two separat...

 PRESS RELEASE

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial...

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported preliminary financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Appointed Brandon Poe as Chief Financial Officer, a seasoned financial executive with experience across the healthcare sectorCompleted enrollment in ...

 PRESS RELEASE

BioStem Technologies Appoints Brandon Poe as Chief Financial Officer

BioStem Technologies Appoints Brandon Poe as Chief Financial Officer Seasoned healthcare CFO with senior experience in capital markets and financial operations across private and publicly traded companies to lead BioStem’s financial team POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Brandon Poe as its Chief Financial Officer (CFO). Mr. Poe has served on BioS...

 PRESS RELEASE

BioStem Technologies to Host Second Quarter 2025 Financial Results Con...

BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025 Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived products for advanced wound care, announces it will release its second quarter 2025 financial results on Thursday, August 14, 2025, and host a conference call and webcast at 4:30 PM ET. The webcast will feature a review of second quarter results and an upd...

 PRESS RELEASE

BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicar...

BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes The Company welcomes CMS’ efforts to reform skin substitute payment policy and will continue to engage with CMS and other stakeholders to optimize the proposed changes POMPANO BEACH, Fla., July 17, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, comments on the Centers for Medicare and Medicaid Services (“CMS”) release of the Calendar...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch